{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T15:37:32Z","timestamp":1787499452560,"version":"build-2736575974"},"reference-count":57,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,6,1]],"date-time":"2025-06-01T00:00:00Z","timestamp":1748736000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,20]],"date-time":"2025-03-20T00:00:00Z","timestamp":1742428800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006392","name":"Centre Hospitalier Universitaire Vaudois","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006392","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100017781","name":"Division of Gastroenterology and Hepatology, School of Medicine, Indiana University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017781","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001711","name":"Swiss National Science Foundation","doi-asserted-by":"publisher","award":["320030-219506"],"award-info":[{"award-number":["320030-219506"]}],"id":[{"id":"10.13039\/501100001711","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jthjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Thrombosis and Haemostasis"],"published-print":{"date-parts":[[2025,6]]},"DOI":"10.1016\/j.jtha.2025.03.011","type":"journal-article","created":{"date-parts":[[2025,3,22]],"date-time":"2025-03-22T05:17:10Z","timestamp":1742620630000},"page":"1938-1952","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Effect of direct oral anticoagulants in cirrhosis: an in vitro study"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5348-8498","authenticated-orcid":false,"given":"Cindy","family":"Pereira Portela","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debora","family":"Bertaggia Calderara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elise","family":"Mdawar-Bailly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Aliotta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Veuthey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas A.","family":"Gautier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darius","family":"Moradpour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Montserrat","family":"Fraga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maxime G.","family":"Zermatten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9686-9920","authenticated-orcid":false,"given":"Lorenzo","family":"Alberio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtha.2025.03.011_bib1","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1053\/j.gastro.2009.08.045","article-title":"An imbalance of pro- vs anti-coagulation factors in plasma from patients with cirrhosis","volume":"137","author":"Tripodi","year":"2009","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtha.2025.03.011_bib2","doi-asserted-by":"crossref","first-page":"2135","DOI":"10.1002\/hep.31201","article-title":"Hemostatic alterations in patients with cirrhosis: from primary hemostasis to fibrinolysis","volume":"71","author":"Zermatten","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2025.03.011_bib3","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1053\/j.gastro.2019.03.070","article-title":"AGA clinical practice update: coagulation in cirrhosis","volume":"157","author":"O\u2019Leary","year":"2019","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtha.2025.03.011_bib4","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2023.01.010","article-title":"Haemostasis in cirrhosis: understanding destabilising factors during acute decompensation","volume":"78","author":"Zanetto","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jtha.2025.03.011_bib5","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1111\/liv.15183","article-title":"Haemostatic alterations in patients with cirrhosis and hepatocellular carcinoma: laboratory evidence and clinical implications","volume":"42","author":"Zanetto","year":"2022","journal-title":"Liver Int"},{"key":"10.1016\/j.jtha.2025.03.011_bib6","doi-asserted-by":"crossref","first-page":"1327","DOI":"10.1002\/hep.31443","article-title":"Acute kidney injury in decompensated cirrhosis is associated with both hypo-coagulable and hyper-coagulable features","volume":"72","author":"Zanetto","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2025.03.011_bib7","doi-asserted-by":"crossref","first-page":"G171","DOI":"10.1152\/ajpgi.00402.2017","article-title":"Role of the blood coagulation cascade in hepatic fibrosis","volume":"315","author":"Pant","year":"2018","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"10.1016\/j.jtha.2025.03.011_bib8","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1016\/j.clinre.2011.03.011","article-title":"The role of hypercoagulability in liver fibrogenesis","volume":"35","author":"Anstee","year":"2011","journal-title":"Clin Res Hepatol Gastroenterol"},{"key":"10.1016\/j.jtha.2025.03.011_bib9","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1053\/j.gastro.2012.07.018","article-title":"Enoxaparin prevents portal vein thrombosis and liver decompensation in patients with advanced cirrhosis","volume":"143","author":"Villa","year":"2012","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jtha.2025.03.011_bib10","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.jhep.2023.02.023","article-title":"Anticoagulation improves survival in patients with cirrhosis and portal vein thrombosis: the IMPORTAL competing-risk meta-analysis","volume":"79","author":"Guerrero","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jtha.2025.03.011_bib11","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1111\/j.1538-7836.2012.04824.x","article-title":"Increased anticoagulant response to low-molecular-weight heparin in plasma from patients with advanced cirrhosis","volume":"10","author":"Senzolo","year":"2012","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib12","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1111\/j.1478-3231.2010.02358.x","article-title":"Low-molecular-weight heparin in patients with advanced cirrhosis","volume":"31","author":"Bechmann","year":"2011","journal-title":"Liver Int"},{"key":"10.1016\/j.jtha.2025.03.011_bib13","doi-asserted-by":"crossref","first-page":"666","DOI":"10.1111\/bjh.12593","article-title":"Routine coagulation assays underestimate levels of antithrombin-dependent drugs but not of direct anticoagulant drugs in plasma from patients with cirrhosis","volume":"163","author":"Potze","year":"2013","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.03.011_bib14","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1160\/th15-04-0354","article-title":"Role of exosite binding modulators in the inhibition of Fxa by TFPI","volume":"115","author":"Peraramelli","year":"2016","journal-title":"Thromb Haemost"},{"issue":"Supplement","key":"10.1016\/j.jtha.2025.03.011_bib15","doi-asserted-by":"crossref","first-page":"64S","DOI":"10.1378\/chest.119.1_suppl.64S","article-title":"Heparin and low-molecular-weight heparin: mechanisms of action, pharmacokinetics, dosing, monitoring, efficacy, and safety","volume":"119","author":"Hirsh","year":"2001","journal-title":"Chest"},{"issue":"Supplement","key":"10.1016\/j.jtha.2025.03.011_bib16","doi-asserted-by":"crossref","first-page":"e44S","DOI":"10.1378\/chest.11-2292","article-title":"Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines","volume":"141","author":"Ageno","year":"2012","journal-title":"Chest"},{"key":"10.1016\/j.jtha.2025.03.011_bib17","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.dld.2021.07.039","article-title":"Efficacy and safety of direct oral anticoagulants versus vitamin K antagonist for portal vein thrombosis in cirrhosis: a systematic review and meta-analysis","volume":"54","author":"Koh","year":"2022","journal-title":"Dig Liver Dis"},{"key":"10.1016\/j.jtha.2025.03.011_bib18","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1007\/s10557-020-07065-y","article-title":"Efficacy and safety of direct oral anticoagulants in patients with atrial fibrillation and liver disease: a meta-analysis and systematic review","volume":"35","author":"Huang","year":"2021","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jtha.2025.03.011_bib19","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1007\/s40256-021-00482-w","article-title":"Comparison of the efficacy and safety of direct oral anticoagulants and vitamin K antagonists in patients with atrial fibrillation and concomitant liver cirrhosis: a systematic review and meta-analysis","volume":"22","author":"Lee","year":"2022","journal-title":"Am J Cardiovasc Drugs"},{"key":"10.1016\/j.jtha.2025.03.011_bib20","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1093\/qjmed\/hcz127","article-title":"Safety of direct oral anticoagulants in patients with cirrhosis: a systematic review and meta-analysis","volume":"112","author":"Lapumnuaypol","year":"2019","journal-title":"QJM"},{"key":"10.1016\/j.jtha.2025.03.011_bib21","doi-asserted-by":"crossref","DOI":"10.1111\/eci.13397","article-title":"CAR. Direct oral anticoagulants and advanced liver disease: a systematic review and meta-analysis","volume":"51","author":"Menichelli","year":"2021","journal-title":"Eur J Clin Invest"},{"key":"10.1016\/j.jtha.2025.03.011_bib22","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.thromres.2024.03.024","article-title":"Effectiveness and safety of direct oral anticoagulants among patients with non-valvular atrial fibrillation and liver disease: a multinational cohort study","volume":"237","author":"Douros","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.03.011_bib23","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.7326\/M23-3067","article-title":"Comparative effectiveness and safety of apixaban, rivaroxaban, and warfarin in patients with cirrhosis and atrial fibrillation : a nationwide cohort study","volume":"177","author":"Simon","year":"2024","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jtha.2025.03.011_bib24","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1111\/liv.13882","article-title":"In vitro efficacy of pro- and anticoagulant strategies in compensated and acutely ill patients with cirrhosis","volume":"38","author":"Lisman","year":"2018","journal-title":"Liver Int"},{"key":"10.1016\/j.jtha.2025.03.011_bib25","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0088390","article-title":"Differential in vitro inhibition of thrombin generation by anticoagulant drugs in plasma from patients with cirrhosis","volume":"9","author":"Potze","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.jtha.2025.03.011_bib26","doi-asserted-by":"crossref","first-page":"1435","DOI":"10.1002\/hep.27350","article-title":"Decreased in vitro anticoagulant potency of Rivaroxaban and Apixaban in plasma from patients with cirrhosis","volume":"61","author":"Potze","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.jtha.2025.03.011_bib27","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1182\/blood.2020005319","article-title":"Anticoagulant activity of edoxaban in patients with cirrhosis","volume":"136","author":"Bos","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.jtha.2025.03.011_bib28","article-title":"Biomarkers of liver dysfunction correlate with a prothrombotic and not with a prohaemorrhagic profile in patients with cirrhosis","volume":"2","author":"Zermatten","year":"2020","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jtha.2025.03.011_bib29","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1002\/rth2.12318","article-title":"Thrombin generation in a woman with heterozygous factor V Leiden and combined oral contraceptives: a case report","volume":"4","author":"Zermatten","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib30","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1111\/jth.13912","article-title":"Laboratory testing in patients treated with direct oral anticoagulants: a practical guide for clinicians","volume":"16","author":"Douxfils","year":"2018","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib31","doi-asserted-by":"crossref","DOI":"10.1155\/2023\/9511499","article-title":"To measure or not to measure: direct oral anticoagulant laboratory assay monitoring in clinical practice","volume":"2023","author":"Ahuja","year":"2023","journal-title":"Adv Hematol"},{"key":"10.1016\/j.jtha.2025.03.011_bib32","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1055\/a-1113-0655","article-title":"Does one dose really fit all? On the monitoring of direct oral anticoagulants: a review of the literature","volume":"40","author":"Moner-Banet","year":"2020","journal-title":"Hamostaseologie"},{"key":"10.1016\/j.jtha.2025.03.011_bib33","doi-asserted-by":"crossref","first-page":"2907","DOI":"10.1111\/jth.15529","article-title":"Thrombin generation assays are versatile tools in blood coagulation analysis: a review of technical features, and applications from research to laboratory routine","volume":"19","author":"Depasse","year":"2021","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib34","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.thromres.2011.06.031","article-title":"Rivaroxaban: quantification by anti-FXa assay and influence on coagulation tests: a study in 9 Swiss laboratories","volume":"129","author":"Asmis","year":"2012","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.03.011_bib35","doi-asserted-by":"crossref","DOI":"10.3389\/fcvm.2021.717939","article-title":"Automated thrombin generation assay for rivaroxaban, apixaban, and edoxaban measurements","volume":"8","author":"Meihandoest","year":"2021","journal-title":"Front Cardiovasc Med"},{"key":"10.1016\/j.jtha.2025.03.011_bib36","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.jhep.2016.10.011","article-title":"Reply to: \"Procoagulant imbalance in patients with non-alcoholic fatty liver disease\"","volume":"66","author":"Potze","year":"2017","journal-title":"J Hepatol"},{"key":"10.1016\/j.jtha.2025.03.011_bib37","doi-asserted-by":"crossref","first-page":"1539","DOI":"10.1111\/ijlh.13618","article-title":"Plasma levels do not predict thrombin generation in patients taking direct oral anticoagulants","volume":"43","author":"Metze","year":"2021","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.03.011_bib38","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1002\/rth2.12044","article-title":"Assessment of the effect of direct oral anticoagulants dabigatran, rivaroxaban, and apixaban in healthy male volunteers using a thrombin generation assay","volume":"1","author":"Artang","year":"2017","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib39","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1002\/rth2.12340","article-title":"Direct oral anticoagulant plasma levels and thrombin generation on ST Genesia system","volume":"4","author":"Pfrepper","year":"2020","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib40","doi-asserted-by":"crossref","first-page":"e426","DOI":"10.1016\/S2352-3026(16)30079-5","article-title":"Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2\/3, non-inferiority trial","volume":"3","author":"Cohen","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.03.011_bib41","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1002\/rth2.12497","article-title":"Anticoagulated patients exhibit intact endogenous thrombin potential using ST Genesia unlike the Calibrated Automated Thrombogram","volume":"5","author":"Helin","year":"2021","journal-title":"Res Pract Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib42","doi-asserted-by":"crossref","first-page":"e403","DOI":"10.1016\/S2352-3026(16)30107-7","article-title":"Rivaroxaban to treat thrombotic antiphospholipid syndrome","volume":"3","author":"Urbanus","year":"2016","journal-title":"Lancet Haematol"},{"key":"10.1016\/j.jtha.2025.03.011_bib43","doi-asserted-by":"crossref","first-page":"e11","DOI":"10.1111\/ijlh.12767","article-title":"Effect of Rivaroxaban on thrombin generation in vivo. A study in obese patients","volume":"40","author":"Bertaggia-Calderara","year":"2018","journal-title":"Int J Lab Hematol"},{"key":"10.1016\/j.jtha.2025.03.011_bib44","first-page":"505","article-title":"Differential effect of direct oral anticoagulants on thrombin generation and fibrinolysis in patients with atrial fibrillation and venous thromboembolism","volume":"20","author":"Dirienzo","year":"2022","journal-title":"Blood Transfus"},{"key":"10.1016\/j.jtha.2025.03.011_bib45","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.thromres.2024.03.006","article-title":"Intrinsic coagulant potential modulates anticoagulant efficacy of rivaroxaban","volume":"237","author":"Pereira Portela","year":"2024","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.03.011_bib46","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2019.102408","article-title":"Can we use NOACS in APS?","volume":"18","author":"Peleg","year":"2019","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.jtha.2025.03.011_bib47","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1016\/j.thromres.2018.10.005","article-title":"The anticoagulant effect of dabigatran is reflected in the lag time and time-to-peak, but not in the endogenous thrombin potential or peak, of thrombin generation","volume":"171","author":"Bloemen","year":"2018","journal-title":"Thromb Res"},{"key":"10.1016\/j.jtha.2025.03.011_bib48","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1111\/j.1538-7836.2010.03822.x","article-title":"The paradoxical stimulation by a reversible thrombin inhibitor of thrombin generation in plasma measured with thrombinography is caused by \u03b12-macroglobulin-thrombin","volume":"8","author":"Wagenvoord","year":"2010","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib49","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1111\/j.1365-2141.2007.06834.x","article-title":"The contribution of \u03b12-macroglobulin thrombin to the endogenous thrombin potential","volume":"139","author":"Hemker","year":"2007","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtha.2025.03.011_bib50","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1111\/jth.15647","article-title":"Alpha-2-macroglobulin in hemostasis and thrombosis: An underestimated old double-edged sword","volume":"20","author":"Lagrange","year":"2022","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib51","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0168-8278(23)00442-7","article-title":"GS-003 - Rivaroxaban improves survival and decompensation in cirrhotic patients with moderate liver dysfunction. Double-blind, placebo-controlled trial","volume":"78","author":"Puente Sanchez","year":"2023","journal-title":"J Hepatol"},{"key":"10.1016\/j.jtha.2025.03.011_bib52","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1016\/j.jtha.2023.10.008","article-title":"Whole blood thrombin generation shows a significant hypocoagulable state in patients with decompensated cirrhosis","volume":"22","author":"Zanetto","year":"2024","journal-title":"J Thromb Haemost"},{"key":"10.1016\/j.jtha.2025.03.011_bib53","article-title":"Impaired whole blood thrombin generation is associated with procedure-related bleeding in acutely decompensated cirrhosis","author":"Zanetto","year":"2024","journal-title":"J Hepatol"},{"key":"10.1016\/j.jtha.2025.03.011_bib54","article-title":"Direct oral anticoagulants in cirrhosis: rationale and current evidence","volume":"6","author":"Pereira Portela","year":"2024","journal-title":"JHEP Rep"},{"key":"10.1016\/j.jtha.2025.03.011_bib55","article-title":"Trends and the course of liver cirrhosis and its complications in Germany: nationwide population-based study (2005 to 2018)","volume":"12","author":"Gu","year":"2022","journal-title":"Lancet Reg Health Eur"},{"key":"10.1016\/j.jtha.2025.03.011_bib56","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1038\/s41575-023-00759-2","article-title":"Global epidemiology of cirrhosis - aetiology, trends and predictions","volume":"20","author":"Huang","year":"2023","journal-title":"Nat Rev Gastroenterol Hepatol"},{"key":"10.1016\/j.jtha.2025.03.011_bib57","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.jhep.2014.03.013","article-title":"Procoagulant imbalance in patients with non-alcoholic fatty liver disease","volume":"61","author":"Tripodi","year":"2014","journal-title":"J Hepatol"}],"container-title":["Journal of Thrombosis and Haemostasis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001850?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1538783625001850?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T21:11:33Z","timestamp":1762549893000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1538783625001850"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,6]]},"references-count":57,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025,6]]}},"alternative-id":["S1538783625001850"],"URL":"https:\/\/doi.org\/10.1016\/j.jtha.2025.03.011","relation":{},"ISSN":["1538-7836"],"issn-type":[{"value":"1538-7836","type":"print"}],"subject":[],"published":{"date-parts":[[2025,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effect of direct oral anticoagulants in cirrhosis: an in vitro study","name":"articletitle","label":"Article Title"},{"value":"Journal of Thrombosis and Haemostasis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtha.2025.03.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Author(s). Published by Elsevier Inc. on behalf of International Society on Thrombosis and Haemostasis.","name":"copyright","label":"Copyright"}]}}